Novartis acquires Vedere Bio to advance optogenetic gene therapy for vision restoration

In a significant acquisition that could reshape the landscape of gene therapy for vision restoration, Swiss pharmaceutical giant Novartis has acquired Vedere Bio, a US-based ... Read More